Aethlon Medical Inc. announced that it has established Exosome Sciences, Inc. as a wholly owned subsidiary of the company. ESI will seek to leverage the recent discovery that the Hemopurifier®, a medical device developed by the company as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The company will contribute into ESI all exosome-related patents and patents pending.

Aethlon Medical Inc. announced that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream. During invitro studies, the Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30 minutes, 80% of the virus in two hours, and a 96% reduction of H1N1 was observed at six hours. The studies were performed by third party researchers approved by the United States Department of Health and Human Services (HHS) to house and conduct research on the current pandemic strains of H1N1 virus.

Aethlon Medical Inc. - Conference Presentation Calls